BioSpace News Archive

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will now host the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of meeting participants. As previously an

NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer cell therapies, announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for SNK01 in combination with trastuzumab or cetuximab for the treatment of advanced/metastatic HER2- or EGFR- expressing cancers.

Appointment of seasoned women’s health marketing executive is a key step in the transition to a fully-integrated drug development and commercial company with initial focus on vaginal yeast infection

The Company plans to present trial data along with a proposed Phase 3 development program in an End of Phase 2 meeting with the FDA before the end of this year

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abstracts were accepted at this year’s American Society of Clinical Oncology (ASCO) Virtual Scientific Program. Both abstracts evaluate BeyondSpring’s lead late-stage asset, Plinabulin, alongside Neulasta (pegfilgrastim), a long-lasting G-

Expansion of the CAVATICA Platform to Australia Enables Harmonized Analysis of Geographically Separated and Jurisdictionally Protected Data Resources

The self-administered COVID-19 sample collection kit integrates comprehensive telehealth support with the ease and convenience of at-home saliva collection.

Respira Technologies, Inc., a health-technology platform development company, announced today the launch of its pharmaceutical focused commercial development program for the RespiRxTM drug delivery device platform.

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that it has completed the acquisition of Granules OmniChem Private Limited, purchasing the remaining 50 percent ownership interest from its joint venture partner, Granules

BIOMODEX, a pioneering digital health company that offers a unique and enhanced 3D printed solution for patient-specific rehearsal and physician training, today announced that Karl Schweitzer has been elected Chair of the Board of Directors, effective immediately.